Suven Life Sciences has achieved satisfactory performance during the quarter ended September 2011. It posted a net profit growth of 9.1 per cent to Rs.2.56 crore as against Rs.2.33 crore in the corresponding period of last year. Its EBDITA went up by 23 per cent to Rs.4.01 crore from Rs.3.26 crore. The company's net sales increased by 30.2 per cent to Rs.48.04 crore from Rs.36.91 crore. The income from CRAMS increased by 38.7 per cent to Rs.43.59 crore, but its income from services (DDDSS) declined by 20.1per cent to Rs.4.54 crore.
For the first half its net profit improved by 2.4 per cent to Rs.5.92 crore from Rs.5.78 crore and its net profit increased by 27.3 per cent to Rs.92.68 crore from Rs.72.83 crore. Its EBDITA moved up by 19.8 per cent to Rs.9.38 core from Rs.7.83 crore.